Eyefinity vs Bristol Myers Squibb
Side-by-side comparison of AI visibility scores, market position, and capabilities
Optometry and optical PMS owned by VSP Global, serving independent eyecare practices across the US. Rancho Cordova CA; OfficeMate covers scheduling, billing, and EHR; iMedicWare handles optical point-of-sale and lab orders;
About
Eyefinity is a Rancho Cordova, California-based optometry and optical practice management software company owned by VSP Global, the largest vision care benefits plan in the United States. Eyefinity provides practice management, electronic health records, and optical lab connectivity tools specifically designed for independent optometrists and optician-led optical retail businesses. The company's products include OfficeMate for practice scheduling, billing, and medical records; ExamWRITER for clinical charting and electronic prescriptions; and iMedicWare for optical point-of-sale and lab order management. Eyefinity's products are used by tens of thousands of eye care professionals across the U.S., many of whom are part of the VSP network of independent optometrists.\n\nEyefinity's connection to VSP Global gives it several advantages in the independent optometry market. VSP's vision care network includes a large proportion of independent optometrists who are naturally inclined toward Eyefinity software because of the seamless VSP insurance eligibility verification and claim submission integration that simplifies the billing workflow for VSP patients—which constitute a significant portion of most private-practice optometry patient volumes. This network integration effectively makes Eyefinity the path of least resistance for VSP-affiliated optometrists seeking practice management software, creating a built-in distribution advantage.\n\nEyefinity has been modernizing its product portfolio through cloud-based offerings and improved user interfaces as competitive pressure from newer optometry software entrants increases. The company competes with Compulink Healthcare Solutions, Revolution EHR, and Crystal Practice Management in the optometry practice management market. Eyefinity differentiates on its VSP integration depth, its large installed base in the VSP network, and the operational trust that comes from being backed by the dominant vision care benefits plan in the United States.
Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.
About
Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.